<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"> 
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">BMC Infect Dis</journal-id><journal-title-group><journal-title>BMC Infectious Diseases</journal-title></journal-title-group><issn pub-type="epub">1471-2334</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmcid">12366110</article-id><article-id pub-id-type="pmid">40830432</article-id>
<article-id pub-id-type="publisher-id">11419</article-id><article-id pub-id-type="doi">10.1186/s12879-025-11419-y</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>The silent legacy of COVID-19: exploring genomic instability in long-term COVID-19 survivors</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0739-9654</contrib-id><name><surname>Abiri</surname><given-names>Elaheh</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Abiri</surname><given-names>Ali</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9199-0382</contrib-id><name><surname>Daneshi</surname><given-names>Salman</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-5998-5209</contrib-id><name><surname>Raesi</surname><given-names>Rasoul</given-names></name><address><email>Raesi.br881@gmail.com</email></address><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03v4m1x12</institution-id><institution-id institution-id-type="GRID">grid.411973.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 0611 8472</institution-id><institution>Department of Cellular and Molecular Biology, School of Biology, Institute of Biological Sciences, </institution><institution>Damghan University, </institution></institution-wrap>Damghan, Iran </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05a2cfm07</institution-id><institution-id institution-id-type="GRID">grid.508789.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 0493 998X</institution-id><institution>Department of Computer, Da.C., </institution><institution>Islamic Azad University, </institution></institution-wrap>Damghan, Iran </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00mz6ad23</institution-id><institution-id institution-id-type="GRID">grid.510408.8</institution-id><institution-id institution-id-type="ISNI">0000 0004 4912 3036</institution-id><institution>Department of Public Health, School of Health, </institution><institution>Jiroft University of Medical Sciences, </institution></institution-wrap>Jiroft, Iran </aff><aff id="Aff4"><label>4</label>Department of Public Health, Torbat Jam Faculty of Medical Sciences, School of Health, Torbat Jam, Iran </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04sfka033</institution-id><institution-id institution-id-type="GRID">grid.411583.a</institution-id><institution-id institution-id-type="ISNI">0000 0001 2198 6209</institution-id><institution>Department of Health Services Management, School of Health, </institution><institution>Mashhad University of Medical Sciences, </institution></institution-wrap>Mashhad, Iran </aff></contrib-group><pub-date pub-type="epub"><day>19</day><month>8</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>19</day><month>8</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>25</volume><elocation-id>1041</elocation-id><history><date date-type="received"><day>17</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>22</day><month>7</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Persistent symptoms and complications reported by many patients for more than four weeks after contracting coronavirus disease 2019 (COVID-19) are referred to as post-COVID-19 syndrome. These persistent symptoms can occur in individuals with both mild and severe COVID-19, though the underlying pathophysiological mechanisms remain poorly understood. This study aims to explore post-COVID-19 syndrome from a biological perspective, focusing on genomic instability.</p></sec><sec><title>Methods</title><p id="Par2">In this cross-sectional study, the comet assay method was employed in March 2024 to evaluate the level of DNA damage in 29 patients to examine the post-COVID-19 syndrome state at Kausar Semnan Hospital in Iran. Levels of DNA damage were assessed using the alkaline comet assay in patients hospitalized for COVID-19, four weeks after a positive RT-PCR test. Patients were categorized based on pneumonia severity: mild (11 patients in non-ICU), moderate (10 patients in ICU and non-intubated), and severe/critical (8 patients in ICU and intubated). Ten healthy individuals who tested negative for COVID-19 were considered as a control group. Data were analyzed using descriptive and inferential statistical tests at a significance level of <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01 in GraphPad Prism 9 software.</p></sec><sec><title>Results</title><p id="Par3">Post-COVID-19 patients exhibited significantly higher levels of DNA damage compared to healthy controls. The highest DNA damage was observed in intubated-ICU patients (mean DNA damage: 29.5%), followed by non-intubated-ICU patients (mean: 24.3%), non-ICU patients (mean: 19.1%), and healthy controls (mean: 9.4%). These findings suggest a clear correlation between COVID-19 severity and increased genomic instability.</p></sec><sec><title>Conclusion</title><p id="Par4">The results of this study highlight the prevalence of DNA damage in post-COVID-19 patients, which may explain long-term genomic instability and associated health complications. The findings underscore the importance of further research into the pathophysiological mechanisms of post-COVID-19 syndrome, particularly its impact on genomic stability. This study contributes to the growing evidence that post-COVID-19 syndrome is a complex condition with virus-specific abnormalities affecting multiple biological pathways. Future studies should focus on understanding these mechanisms to develop targeted interventions for long-term COVID-19 survivors.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>COVID-19</kwd><kwd>Lymphopenia</kwd><kwd>Comet assay</kwd><kwd>DNA damage</kwd><kwd>Post-COVID-19</kwd><kwd>Long-term COVID-19</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par41">Respiratory symptoms associated with coronaviruses, characterized by their distinctive crown-like spike proteins (derived from the Latin word &#x0201c;corona&#x0201d;) [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>], have gained significant attention due to the emergence of SARS-CoV-2. This virus has not only caused acute respiratory infections but also led to severe organ damage, contributing to an alarming rise in global morbidity and mortality rates [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. While many individuals recover from the acute phase of COVID-19, a growing body of research indicates that the sequelae of SARS-CoV-2 infection could profoundly impact patients&#x02019; quality of life and their ability to resume daily activities and employment [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. Common persistent symptoms include dyspnea, fatigue, anosmia, chest pain, ageusia, cognitive impairment, and arthralgia, which may manifest weeks after the initial infection [<xref ref-type="bibr" rid="CR7">7</xref>&#x02013;<xref ref-type="bibr" rid="CR9">9</xref>]. The pathophysiological mechanisms behind these lingering symptoms remain poorly understood, but they appear to stem from a complex interplay of immune dysregulation, chronic inflammation, and potential direct viral effects on host tissues. Notably, the infection prompts an innate immune response characterized by an overproduction of inflammatory cytokines and a procoagulant state, which may contribute to cellular damage [<xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>]. Recent studies have begun to explore the implications of DNA damage in this context, suggesting that viral manifestations may induce genomic instability, thus providing a rationale to investigate DNA damage as a potential underlying mechanism contributing to long-COVID symptoms. However, the direct causal links between DNA damage and specific long-COVID symptoms necessitate careful examination, particularly given that the current study is observational and cannot definitively infer causation but may identify correlations [<xref ref-type="bibr" rid="CR13">13</xref>&#x02013;<xref ref-type="bibr" rid="CR15">15</xref>]. It is essential to acknowledge numerous potential confounders that might contribute to observed DNA damage, including systemic inflammation, oxidative stress, ICU interventions, pharmacologic exposures, and nutritional states [<xref ref-type="bibr" rid="CR16">16</xref>&#x02013;<xref ref-type="bibr" rid="CR18">18</xref>]. The variability in symptom presentation among individuals recovering from COVID-19 may also be significantly influenced by these factors, alongside age, pre-existing medical conditions, and the severity of the acute infection [<xref ref-type="bibr" rid="CR19">19</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref>]. Understanding these complexities is crucial as ongoing investigations strive to untangle the multifactorial nature of post-COVID-19 syndrome and identify effective therapeutic strategies that address the broad spectrum of symptoms linked to this condition [<xref ref-type="bibr" rid="CR22">22</xref>]. Moreover, a critical understanding of the necessity for continuous patient care following acute COVID-19 is essential for addressing symptom persistence beyond four weeks [<xref ref-type="bibr" rid="CR18">18</xref>]. Rehabilitation programs that incorporate physical and cognitive therapies are currently being evaluated to aid in recovery, emphasizing the importance of a comprehensive, patient-centered approach that considers mental health as well, given the prevalence of depression and anxiety among individuals recovering from the illness [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. Ultimately, prioritizing patient education and support can empower individuals to seek medical assistance and engage in practices that promote their recovery and overall well-being [<xref ref-type="bibr" rid="CR25">25</xref>]. In summary, while recovery from acute COVID-19 is common, post-COVID-19 syndrome&#x02019;s emergence poses significant challenges for healthcare providers. The exploration of DNA damage as a possible contributing factor to long-COVID symptoms is a novel area of inquiry that may yield crucial insights, necessitating further research focused on this potential linkage to enhance clinical outcomes for affected patients.</p></sec><sec id="Sec2"><title>Methods</title><p id="Par42">The study protocol was approved by the institutional review board (Ethics Committee) of Azad University of Damghan, and all procedures were performed according to the Declaration of Helsinki (study code of ethics: IR.IAU.DAMGHAN.REC.1400.005).</p><sec id="Sec3"><title>Participants</title><p id="Par43">In this cross-sectional study, levels of DNA damage were assessed using the alkaline comet assay in patients hospitalized for COVID-19, four weeks after a positive RT-PCR test. A total of 29 patients admitted to Kausar Semnan Hospital in Iran in December 2024 were selected via a convenience sampling method and categorized based on pneumonia severity: mild (11 patients in non-ICU), moderate (10 patients in ICU and non-intubated), and severe/critical (8 patients in ICU and intubated). Ten healthy individuals who tested negative for COVID-19 were considered as a control group. Participants received informed written consent and met the following criteria: age over 18 years and under 60 years old, non-smokers, no infectious disease (at least 30 days prior to study entry), not pregnant, and no underlying medical conditions.</p><p id="Par44">Oropharyngeal and nasopharyngeal swabs were collected from patients and controls using sterile swabs. RNA was extracted from the swab samples using the Perkin Elmer Chemagic 360 system according to the manufacturer&#x02019;s instructions. Briefly, the swabs were placed in viral transport medium, and RNA was isolated using magnetic bead-based extraction. The extracted RNA was subjected to reverse transcription-polymerase chain reaction (RT-PCR) using the Viasure SARS-CoV-2 RT-PCR detection kit (Cer Test Biotec SL, Spain). The kit targets the N1 and N2 genes of SARS-CoV-2. Each reaction mix included 5&#x000a0;&#x000b5;l of extracted RNA and 15&#x000a0;&#x000b5;l of master mix (containing primers, probes, and enzymes). The RT-PCR was performed under the following conditions: reverse transcription at 50&#x000a0;&#x000b0;C for 15&#x000a0;min, initial denaturation at 95&#x000a0;&#x000b0;C for 2&#x000a0;min, and amplification for 45 cycles at 95&#x000a0;&#x000b0;C for 15&#x000a0;s and 60&#x000a0;&#x000b0;C for 30&#x000a0;s.</p></sec><sec id="Sec4"><title>Cycle threshold (Ct) values and classification</title><p id="Par45">The Ct values were recorded for each sample, with lower Ct values indicating higher viral loads. Based on the Ct values, patients were classified into the following severity groups: mild (non-ICU): Ct values&#x02009;&#x0003e;&#x02009;30 (lower viral load), moderate (non-intubated ICU): Ct values 20&#x02013;30 (moderate viral load), severe/critical (intubated ICU): Ct values&#x02009;&#x0003c;&#x02009;20 (high viral load). Ten healthy individuals who tested negative for COVID-19 (Ct values&#x02009;&#x02265;&#x02009;40 or undetectable) were included as the control group.</p></sec><sec id="Sec5"><title>Comet assay protocol</title><p id="Par46">Blood samples were collected eight hours prior to the comet assay. Using Singh et al.&#x02018;s standard technique with modifications, 2&#x000a0;ml of heparinized blood was mixed with 2&#x000a0;ml of Ficoll and centrifuged at 1500&#x000a0;rpm for 30&#x000a0;min at 4&#x000a0;&#x000b0;C to isolate peripheral blood mononuclear cells (PBMCs). A suspension of 10&#x000a0;&#x000b5;l of PBMCs was mixed with 80&#x000a0;&#x000b5;l of 0.7% low-melting-point agarose at 37&#x000a0;&#x000b0;C, and the mixture was placed on slides under coverslips at 4&#x000a0;&#x000b0;C for solidification. The slides were then treated with a lysing solution containing Tris-HCl, EDTA, NaCl, SDS, and Triton X100 at low temperature (4&#x000a0;&#x000b0;C) before being incubated with alkaline electrophoresis buffer for 30&#x000a0;min (10&#x000a0;M NaOH and 200 mM EDTA-2Na) in an electrophoresis apparatus (25&#x000a0;V/300&#x000a0;mA for 25&#x000a0;min). Post-drying, slides were neutralized, stained with ethidium bromide, and analyzed using an Olympus IX71 fluorescence microscope. Comet assay images were analyzed quantitatively with OpenComet software. The damage index (DI) was calculated using formulas from Ivancsits et al. [<xref ref-type="bibr" rid="CR26">26</xref>] and Li et al. [<xref ref-type="bibr" rid="CR27">27</xref>].</p></sec><sec id="Sec6"><title>Statistical analysis</title><p id="Par47">Descriptive statistics (mean&#x02009;&#x000b1;&#x02009;standard deviation, frequency) were used to present demographic data. Chi-square tests compared demographic variables across groups. To assess differences in comet means, T-tests and paired Wilcoxon signed-rank tests were employed after confirming normality and variance equality with Levene&#x02019;s test and K-S tests. The Mann-Whitney U test was used for comparisons of assessment indices. Spearman&#x02019;s rank correlation coefficient was utilized to evaluate correlations between DNA damage parameters and symptom severity. Statistical significance was set at <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01, and analyses were conducted using GraphPad Prism 9 software.</p></sec></sec><sec id="Sec7"><title>Results</title><p id="Par48">The participant cohort consisted of individuals aged 18&#x02013;59 years, with an average weight (referring to a body mass index (BMI) within the normal range (18.5&#x02013;24.9&#x000a0;kg/m&#x000b2;) [<xref ref-type="bibr" rid="CR28">28</xref>]), without underlying medical conditions, and who had no intake of vitamins C or D, allowing for appropriate comparison with healthy controls. The demographics of COVID-19 patients during the post-COVID-19 period are summarized in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. The intubated-ICU group has the highest median age (46 years), indicating that older individuals are more likely to experience severe COVID-19 requiring intensive care. The non-ICU group has the youngest median age (27 years). Males are more numerous than females in all groups, with the highest proportion in the intubated-ICU group (87.5%). The control group has an equal distribution of males and females (50% each). Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> is a bar graph comparing the prevalence of various symptoms across four groups: healthy controls, non-ICU patients, non-intubated-ICU patients, and intubated-ICU patients. The symptoms listed on the x-axis include dyspnea, chest pain, arthralgia, musculoskeletal pain, widespread myalgia, loss of olfactory and gustatory function, fatigue, tightness of the chest, chills or sweats, and dry cough. The y-axis represents the percentage of individuals within each group experiencing each symptom.</p><p id="Par49">
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Demographics and characteristics of patients infected with long COVID-19</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="7">Number (%)</th></tr><tr><th align="left"/><th align="left">Characteristics</th><th align="left">All (<italic>n</italic>&#x02009;=&#x02009;29)</th><th align="left">Non-ICU (<italic>n</italic>&#x02009;=&#x02009;11)</th><th align="left">Non-intubated-ICU (<italic>n</italic>&#x02009;=&#x02009;10)</th><th align="left">Intubate-ICU (<italic>n</italic>&#x02009;=&#x02009;8)</th><th align="left">Control (<italic>n</italic>&#x02009;=&#x02009;10)</th></tr></thead><tbody><tr><td align="left" rowspan="2">Post-COVID-19</td><td align="left">Age, median (IQR), y</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left"><p>Sex</p><p>Male</p><p>Female</p></td><td align="left"><p>31 (18&#x02013;59)</p><p>21(54.8%)</p><p>8 (45.1%)</p></td><td align="left"><p>27 (18&#x02013;39)</p><p>8 (72.7%)</p><p>3 (27.2%)</p></td><td align="left"><p>38 (30&#x02013;51)</p><p>6(60%)</p><p>4(40%)</p></td><td align="left"><p>46 (46&#x02013;59)</p><p>7 (87.5%)</p><p>1 (12.5%)</p></td><td align="left"><p>28 (20&#x02013;53)</p><p>5 (50%)</p><p>5 (50%)</p></td></tr></tbody></table></table-wrap>
</p><p id="Par50">In Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>, patients with post-COVID-19 syndrome reported a diverse array of symptoms experienced during hospitalization:</p><p id="Par51">Dyspnea: This symptom is present in intubated-ICU patients (63.5%), non-intubated-ICU patients (56.1%), non-ICU patients (41.7%), and healthy subjects (1.6%). Dyspnea is significantly increased in all 3 patient groups compared to healthy subjects (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01), and dyspnea is higher in intubated-ICU patients than in all symptoms across all groups (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01).</p><p id="Par52">Chest pain: This symptom is present in intubated-ICU patients (5.5%), non-intubated-ICU patients (8.3%), non-ICU patients (3.4%), and healthy subjects (1.9%). Chest pain is increased in all 3 patient groups compared to healthy subjects but is significant only in the non-intubated group (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01) and is very mild compared to all symptoms in all patient groups. This symptom is higher in non-intubated-ICU patients compared to other patients (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01).</p><p id="Par53">Arthralgia: This symptom is present in intubated-ICU patients (10.1%), non-intubated-ICU patients (10.3%), non-ICU patients (10.2%), and healthy subjects (1.3%). It is increased in all 3 patient groups compared to healthy subjects (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01) and is very mild compared to all symptoms in all patient groups. There is no significant difference between the 3 patient groups in this symptom (<italic>p</italic>&#x02009;&#x0003e;&#x02009;0.01).</p><p id="Par54">Musculoskeletal pain: This symptom is present in intubated-ICU patients (13.3%), non-intubated-ICU patients (15.6%), non-ICU patients (17.8%), and healthy subjects (1.2%). It is increased in all 3 patient groups compared to healthy subjects (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01) and is very mild compared to all symptoms in all patient groups. This symptom is higher in non-ICU patients than in ICU patients (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01).</p><p id="Par55">Widespread myalgia: This symptom is present in intubated-ICU patients (5.3%), non-intubated-ICU patients (9.1%), non-ICU patients (2.8%), and healthy subjects (1.4%). It is increased in all 3 patient groups compared to healthy subjects (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01) and is very mild compared to all symptoms in all patient groups. This symptom is higher in non-intubated-ICU patients than in other patients but is only significant compared to non-ICU patients (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01).</p><p id="Par56">Loss of smell and taste: This symptom is present in intubated-ICU patients (36.1%), non-intubated ICU patients (19.8%), non-ICU patients (31.3%), and healthy subjects (0%). It is increased in all 3 patient groups compared to healthy subjects (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01) and is of moderate severity compared to all symptoms in all patient groups. This symptom is less common in non-intubated-ICU patients compared to other patients (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01).</p><p id="Par57">Fatigue: This symptom is present in intubated-ICU patients (51.5%), non-intubated-ICU patients (39.9%), non-ICU patients (24.1%), and healthy subjects (0%). It is increased in all 3 patient groups compared to healthy subjects (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01) and is of high severity compared to all symptoms in all patient groups. Fatigue is higher in intubated-ICU patients than in all others (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01).</p><p id="Par58">Tightness of the chest: This symptom is present in intubated-ICU patients (3.4%), non-intubated ICU patients (4.7%), non-ICU patients (2.1%), and healthy subjects (1.9%). It is more common in ICU patients than in healthy subjects, but the difference between any patient groups and healthy subjects is not significant (<italic>p</italic>&#x02009;&#x0003e;&#x02009;0.01). This symptom is less common than all symptoms in all patient groups and is very mild.</p><p id="Par59">Chills or sweats: This symptom is present in intubated-ICU patients (43.2%), non-intubated-ICU patients (37.4%), non-ICU patients (22.2%), and healthy subjects (1.1%). It is more common in all patients than in healthy subjects (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01). There is no significant difference between ICU patients (<italic>p</italic>&#x02009;&#x0003e;&#x02009;0.01), but non-ICU patients are less common than all (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01). This symptom is more severe than all symptoms in all patient groups.</p><p id="Par60">Dry cough: This symptom is present in intubated-ICU patients (45.6%), non-intubated-ICU patients (46.4%), non-ICU patients (33.7%), and healthy subjects (2.4%). It is increased in all patients compared to healthy subjects (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01). There is no significant difference between ICU patients (<italic>p</italic>&#x02009;&#x0003e;&#x02009;0.01), but non-ICU patients show lower frequency than all others (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01). This symptom is more severe than all symptoms in all patient groups.</p><p id="Par61">The Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> illustrates the relationship between disease severity and symptom prevalence. Intubated-ICU patients typically show a higher rate of symptoms, indicating a more severe disease state. Within patient groups, there seems to be a trend of increasing symptom burden with increasing disease severity, evidenced by the higher prevalence of symptoms in intubated-ICU patients compared to non-intubated-ICU patients and non-ICU patients. Dyspnea, loss of smell and taste, fatigue, and chills are significantly more common in patients, especially in intubated-ICU cases.</p><p id="Par62">
<fig id="Fig1"><label>Fig. 1</label><caption><p>Comparative prevalence of clinical symptoms among patient groups with varying disease severity</p></caption><graphic xlink:href="12879_2025_11419_Fig1_HTML" id="d33e720"/></fig>
</p><p id="Par63">An example of DNA damage among the groups studied is depicted in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>, indicating that tail length correlates with the degree of DNA breakage, particularly in the intubated-ICU and non-intubated-ICU groups. The intubated-ICU group exhibited the highest levels of DNA damage during the post-COVID-19 phase, significantly lower than controls. All groups exhibited higher DNA damage when compared to the control group. Among COVID-19 severity phenotypes, the intubated-ICU group showed the most significant damage, followed by non-intubated-ICU patients. In Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>, a cell with a normal nucleus and intact DNA, without a comet-like tail, is seen, which is called intact DNA. A cell with fragmented DNA is seen, where part of the DNA has broken away from the nucleus, forming a comet-like trail. The tail represents the damaged DNA fragments that have migrated due to electrophoresis. The head of the comet is called the nucleus, and the tail is called the DNA fragments. Small, medium, and large tails, which are precisely measured by the software, indicate different degrees of DNA damage. Smaller tails indicate less damage, while longer tails indicate more severe damage.</p><p id="Par64">
<fig id="Fig2"><label>Fig. 2</label><caption><p>Schematic illustration of DNA damage detected using the comet assay technique</p></caption><graphic xlink:href="12879_2025_11419_Fig2_HTML" id="d33e738"/></fig>
</p><p id="Par65">In Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>, the following parameters related to DNA damage were assessed:</p><p id="Par66">Tail Length (&#x000b5;m): The intubated-ICU patients exhibited a mean tail length of 22.4&#x000a0;&#x003bc;m, corresponding to the highest level of DNA damage. In comparison, non-intubated-ICU patients had a tail length of 15.4&#x000a0;&#x003bc;m, non-ICU patients had 7.9&#x000a0;&#x003bc;m, and healthy subjects showed a tail length of 3.8&#x000a0;&#x003bc;m. Each of these parameters indicated a significant increase in DNA damage in all three patient groups compared to healthy individuals (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01), with the highest damage observed in the intubated group.</p><p id="Par67">Tail Intensity (% DNA in tail): This parameter measured the percentage of DNA present in the tail. Intubated-ICU patients had a mean tail intensity of 25.2%, non-intubated-ICU patients 25.8%, non-ICU patients 19.6%, and healthy subjects 5.1%. All three patient groups exhibited increased rates of DNA damage compared to healthy subjects (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01), with the ICU patient group showing a significant increase compared to non-ICU patients (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01).</p><p id="Par68">Tail Moment: This unitless parameter is calculated as the product of tail length (in &#x000b5;m) and tail intensity (expressed as a percentage). The tail moment values for the groups were as follows: 11.5 (intubated-ICU), 6.6 (non-intubated-ICU), 6.1 (non-ICU), and 1.4 (healthy individuals). All groups showed increased tail moment values compared to healthy subjects (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01). No significant difference existed between non-intubated-ICU and non-ICU groups (<italic>p</italic>&#x02009;&#x0003e;&#x02009;0.01), although both had significantly lower tail moments than the intubated-ICU patients (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01).</p><p id="Par69">Tail Factor: This parameter was measured at values of 14.2 for intubated-ICU patients, 10.1 for non-intubated-ICU patients, 5.9 for non-ICU patients, and 3.3 for healthy subjects. Increased tail factor rates were observed in all groups compared to healthy individuals (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01), with the consistent order of damage being: intubated-ICU, non-intubated-ICU, and non-ICU (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01).</p><p id="Par70">Tail DNA Percentage: Measurements showed that the percentage of DNA in the tail was at 10.9% for intubated-ICU patients, 7.1% for non-intubated-ICU patients, 7.2% for non-ICU patients, and 1.1% for healthy subjects. Again, all three patient groups had significantly higher results compared to healthy subjects (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01), with no significant difference between non-intubated-ICU and non-ICU patients (<italic>p</italic>&#x02009;&#x0003e;&#x02009;0.01). Intubated-ICU patients recorded the highest tail DNA percentage. The distribution of DNA damage parameters was noted to be in the following order: tail intensity, tail length, tail moment, tail factor, and tail DNA percentage (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>).</p><p id="Par71">
<fig id="Fig3"><label>Fig. 3</label><caption><p>Is a bar graph comparing the levels of DNA damage across four groups: healthy controls, non-ICU patients, non-intubated-ICU patients, and intubated-ICU patients. The DNA damage is assessed using different parameters: tail length (&#x000b5;m), tail intensity, tail moment, tail factor, and tail DNA percentage. Each bar represents the mean value for each group, with error bars indicating the standard deviation</p></caption><graphic xlink:href="12879_2025_11419_Fig3_HTML" id="d33e797"/></fig>
</p></sec><sec id="Sec8"><title>Discussion</title><p id="Par72">The COVID-19 pandemic has left an indelible mark on global health, with emerging evidence suggesting that even after recovery, many survivors experience persistent symptoms&#x02014;collectively termed post-acute sequelae of SARS-CoV-2 infection (PASC) or long COVID-19. The most prevalent definition indicates that long COVID-19 is characterized by symptoms persisting for more than three months from the onset of the initial symptoms, although various definitions exist. A review of available literature highlights that fatigue and dyspnea (shortness of breath) are the most frequently reported persistent symptoms associated with long COVID-19 [<xref ref-type="bibr" rid="CR29">29</xref>&#x02013;<xref ref-type="bibr" rid="CR32">32</xref>]. The management and care for individuals with post-COVID-19 syndrome are anticipated to present significant challenges for healthcare systems globally. Current findings suggest critical directions for future research, particularly concerning the underlying pathophysiological processes associated with post-COVID-19 syndrome. Although numerous studies have provided intricate biological explanations for this condition, there still remains a gap in our understanding of the physiological pathways and mechanisms involved. As the long-term consequences of COVID-19 become more apparent, further information is expected to inform therapeutic approaches. Persistent abnormalities were observed in the cardiovascular system; for instance, 29% of 79 COVID-19 survivors exhibited radiological signs of ventricular remodeling three months after hospital discharge [<xref ref-type="bibr" rid="CR33">33</xref>]. Miwa et al. [<xref ref-type="bibr" rid="CR34">34</xref>] reported concerning statistics showing that 90% of patients who underwent invasive mechanical ventilation continued to experience lung-related complications 100 days post-treatment, while 47% of those who did not require such ventilation displayed significant, prolonged reductions in pulmonary function. Furthermore, many individuals experience post-acute sequelae after receiving treatment for acute COVID-19. Chopra et al. [<xref ref-type="bibr" rid="CR35">35</xref>] conducted an analysis on the long-term effects of COVID-19 in hospitalized patients, revealing that a notable proportion reported ongoing symptoms like fatigue, dyspnea, and cognitive challenges even months post-discharge. This underscores the critical need for thorough follow-up care for individuals recovering from COVID-19, as many may struggle to regain their prior levels of health and activity [<xref ref-type="bibr" rid="CR36">36</xref>]. The similarities in symptoms between post-COVID-19 syndrome and established autoimmune disorders, such as rheumatoid arthritis and lupus, suggest that shared pathogenic mechanisms may be at work in individuals recovering from COVID-19 [<xref ref-type="bibr" rid="CR37">37</xref>&#x02013;<xref ref-type="bibr" rid="CR39">39</xref>]. This emphasizes the necessity for ongoing research to better elucidate the long-term impacts of COVID-19 on immune function and the potential for targeted therapies to manage these autoimmune manifestations.</p><p id="Par73">This study has highlighted genomic instability&#x02014;increased DNA damage&#x02014;as a potential underlying mechanism for these long-term effects. We explored the relationship between COVID-19 severity, DNA damage, and post-COVID syndrome, drawing on findings comparing healthy controls, non-ICU patients, non-intubated-ICU patients, and intubated-ICU patients. We employed comet assay parameters (tail length, tail intensity, tail moment, tail factor, and tail DNA percentage) to quantify DNA damage. Results revealed a clear dose-dependent relationship between COVID-19 severity and genomic instability: intubated-ICU patients showed the highest DNA damage. Tail intensity (25.8%) and tail length (23.2%) were significantly elevated, indicating severe DNA fragmentation. This group also exhibited the highest prevalence of post-COVID symptoms, including dyspnea (56.1%), fatigue (51.5%), and loss of smell/taste (36.1%). Non-intubated-ICU patients had intermediate damage; tail intensity (25.8%) was comparable to intubated patients, but tail length (15.4%) and tail moment (6.6%) were lower. Symptoms like chest pain (8.3%) and widespread myalgia (9.1%) were more pronounced than in non-ICU patients. Non-ICU patients still exhibited elevated DNA damage. Despite milder acute illness, tail length (7.9%) and tail intensity (19.6%) were significantly higher than in healthy controls. Symptoms such as musculoskeletal pain (17.8%) and fatigue (24.1%) persisted, suggesting long-term cellular dysfunction. The study found strong correlations between DNA damage severity and persistent symptoms, suggesting several mechanistic pathways:</p><p id="Par74">Respiratory Symptoms (dyspnea, dry cough) and oxidative lung damage: Intubated-ICU patients had the highest dyspnea (63.5%) and tail length (23.2%). Mechanical ventilation, hypoxia, and cytokine storms may induce oxidative DNA breaks in lung epithelial cells, which impair long-term respiratory function [<xref ref-type="bibr" rid="CR40">40</xref>]. Fatigue and mitochondrial DNA damage: Fatigue (51.5% in intubated-ICU) correlated with high tail moment (11.5%). SARS-CoV-2 may disrupt mitochondrial function, leading to energy depletion and chronic fatigue [<xref ref-type="bibr" rid="CR41">41</xref>]. Neurological symptoms (loss of smell/taste) and neuronal DNA damage: Viral invasion of olfactory neurons may cause DNA damage that delays neural regeneration [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR43">43</xref>]. Systemic inflammation and musculoskeletal pain: Musculoskeletal pain (17.8% in non-ICU) associated with moderate tail factor (5.9%). Persistent inflammatory cytokines (IL-6, TNF-&#x003b1;) may contribute to DNA damage in muscle and joint tissues [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR45">45</xref>]. The persistence of DNA damage raises concerns about long-term health consequences, including: Unrepaired DNA breaks may lead to oncogenic mutations, particularly in severely affected patients. Chronic genomic instability is linked to telomere shortening and cellular senescence, potentially accelerating aging-related diseases. Damaged DNA fragments may trigger autoantibodies, contributing to autoimmune-like symptoms in long COVID-19 [<xref ref-type="bibr" rid="CR46">46</xref>&#x02013;<xref ref-type="bibr" rid="CR49">49</xref>].</p><p id="Par75">Our study found that higher DNA damage correlates with more severe and persistent symptoms, particularly in ICU survivors. By employing the alkaline comet assay, we demonstrated that post-COVID-19 patients exhibit significantly higher levels of DNA damage compared to healthy controls, with the severity of COVID-19 directly correlating with the extent of genomic instability. The highest levels of DNA damage were observed in intubated-ICU patients, followed by non-intubated-ICU and non-ICU patients. This suggests that the virus&#x02019;s impact on the genome is not merely transient but may persist long after the acute phase of infection. This genomic instability could be a key factor underlying the enigmatic post-COVID-19 syndrome, a condition characterized by persistent symptoms that continue to afflict millions of survivors worldwide. The damage to DNA, as evidenced in this study, may contribute to a cascade of cellular dysfunctions, including impaired repair mechanisms, increased oxidative stress, and potential mutations that could predispose individuals to long-term health complications, such as chronic inflammation, autoimmune disorders, or even malignancies.</p><p id="Par76">This study adds a novel biological dimension to our understanding of post-COVID-19 syndrome, highlighting that the virus&#x02019;s impact extends far beyond the respiratory system. The genomic instability observed in survivors suggests that COVID-19 may leave a lasting imprint on the cellular level, potentially altering the trajectory of health in ways that are only beginning to be understood. This raises critical questions about the long-term consequences of the pandemic and underscores the need for targeted interventions to mitigate these effects. As we move forward, it is imperative to explore the mechanisms driving this genomic instability, whether through direct viral interference, immune-mediated damage, or systemic inflammation&#x02014;and to develop strategies to protect or repair the genome in post-COVID-19 patients. This study serves as a call to action for further research into the biological underpinnings of post-COVID-19 syndrome, with the ultimate goal of improving the quality of life for the millions of survivors who continue to grapple with its silent legacy. Future research should investigate whether this damage is reversible and whether targeted therapies (e.g., antioxidants, anti-inflammatories) can mitigate long-term effects. This review provides significant data aimed at enhancing our understanding of the long-term effects of COVID-19 and the necessity for research on DNA damage associated with specific viral agents. Understanding the physiological changes during COVID-19 could inform the development of subsequent conditions, identify symptom clusters associated with different levels of disease severity, and help clinicians prioritize patient care, allocate resources based on observed symptom burden, and develop prognostic models for predicting disease outcomes. Longitudinal studies are needed to investigate the temporal relationship between symptoms and disease progression, and studies with larger sample sizes are required to confirm the statistical significance of the findings and assess the generalizability of the results to different populations.</p></sec><sec id="Sec9"><title>Conclusion</title><p id="Par77">The findings of this study unveil a silent yet profound legacy of COVID-19: genomic instability as a potential driver of long-term health complications in survivors. In conclusion, COVID-19 is not just a transient infection but a catalyst for long-term genomic disruption, leaving behind a trail of cellular damage that may shape the health of survivors for years to come. Understanding and addressing this silent legacy will be crucial in the ongoing battle against the pandemic&#x02019;s enduring aftermath.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>COVID-19</term><def><p id="Par5">Coronavirus Disease 2019</p></def></def-item><def-item><term>SARS-CoV-2</term><def><p id="Par6">Severe acute respiratory syndrome coronavirus 2</p></def></def-item><def-item><term>ICU</term><def><p id="Par7">Intensive care unit</p></def></def-item><def-item><term>RT-PCR</term><def><p id="Par8">Reverse transcription-polymerase chain reaction</p></def></def-item><def-item><term>PBMCs</term><def><p id="Par9">Peripheral blood mononuclear cells</p></def></def-item><def-item><term>SDS</term><def><p id="Par10">Sodium dodecyl sulfate</p></def></def-item><def-item><term>EDTA</term><def><p id="Par11">Ethylenediaminetetraacetic acid</p></def></def-item><def-item><term>NaOH</term><def><p id="Par12">Sodium hydroxide</p></def></def-item><def-item><term>DI</term><def><p id="Par13">Damage index</p></def></def-item><def-item><term>DNA</term><def><p id="Par14">Deoxyribonucleic acid</p></def></def-item><def-item><term>RNA</term><def><p id="Par15">Ribonucleic acid</p></def></def-item><def-item><term>Ficoll</term><def><p id="Par16">A type of density gradient medium used for cell separation</p></def></def-item><def-item><term>Tris-HCl</term><def><p id="Par17">Tris(hydroxymethyl)aminomethane hydrochloride</p></def></def-item><def-item><term>NaCl</term><def><p id="Par18">Sodium chloride</p></def></def-item><def-item><term>Triton X100</term><def><p id="Par19">A nonionic detergent used in biochemical research</p></def></def-item><def-item><term>K-S test</term><def><p id="Par20">Kolmogorov&#x02013;Smirnov test</p></def></def-item><def-item><term>Mann-Whitney U test</term><def><p id="Par21">A nonparametric test for comparing two independent samples</p></def></def-item><def-item><term>Levene's test</term><def><p id="Par22">A test for equality of variances</p></def></def-item><def-item><term>GraphPad Prism 9</term><def><p id="Par23">A statistical analysis software</p></def></def-item><def-item><term>Perkin Elmer Chemagic 360</term><def><p id="Par24">A device used for RNA extraction</p></def></def-item><def-item><term>Viasure SARS-CoV-2 RT-PCR Detection Kit</term><def><p id="Par25">A diagnostic kit for detecting SARS-CoV-2</p></def></def-item><def-item><term>OpenComet</term><def><p id="Par26">Software for analyzing comet assay images</p></def></def-item><def-item><term>Dyspnea</term><def><p id="Par27">Shortness of breath</p></def></def-item><def-item><term>Arthralgia</term><def><p id="Par28">Joint pain</p></def></def-item><def-item><term>Myalgia</term><def><p id="Par29">Muscle pain</p></def></def-item><def-item><term>Olfactory</term><def><p id="Par30">Related to the sense of smell</p></def></def-item><def-item><term>Gustatory</term><def><p id="Par31">Related to the sense of taste</p></def></def-item><def-item><term>Fatigue</term><def><p id="Par32">Extreme tiredness</p></def></def-item><def-item><term>Dry cough</term><def><p id="Par33">A cough without phlegm</p></def></def-item><def-item><term>Chills or sweats</term><def><p id="Par34">Symptoms of fever or illness</p></def></def-item><def-item><term>Tightness of the chest</term><def><p id="Par35">A sensation of pressure or discomfort in the chest</p></def></def-item><def-item><term>Tail length</term><def><p id="Par36">A measure of DNA damage in the comet assay</p></def></def-item><def-item><term>Tail intensity</term><def><p id="Par37">A measure of the amount of DNA in the comet tail</p></def></def-item><def-item><term>Tail factor</term><def><p id="Par38">The percentage of DNA in the comet tail</p></def></def-item><def-item><term>Tail moment</term><def><p id="Par39">A combined measure of tail length and intensity</p></def></def-item><def-item><term>Tail DNA percentage</term><def><p id="Par40">The percentage of DNA fragments in the comet tail</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#x02019;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We would like to express our sincere gratitude and appreciation to the distinguished Biomedical Research Ethics Committee of Damghan Islamic Azad University, participants in the research, as well as everyone who assisted us in executing this project.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>E.A. conceived the original idea and designed the project. E.A. participated in the design and executed the experiments. E.A, S.D, and R.R discussed the results and strategy. E.A. wrote the manuscript. All authors reviewed, edited, and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This project did not receive any financial support from any non-profit, government, or for-profit financial institutions. Financial support for this research was provided by Dr. Elaheh Abiri.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The datasets generated and/or analyzed during this study are available from the corresponding author upon reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par78">All procedures performed in the study involving human participants were conducted according to the ethical standards of the institutional and national research committee and of the 1975 Helsinki Declaration and its later amendments or comparable ethical standards. This study was approved by the Biomedical Research Ethics Committee of Damghan Islamic Azad University, which issued the study&#x02019;s code of ethics (IR.IAU. DAMGHAN.REC.1400.005). Before data collection, written informed consent was obtained from all subjects participating in the study. To comply with ethical considerations, all medical record information was kept confidential. The names and surnames of participants were not used for data collection, and data collection was carried out after obtaining the code of ethics from Damghan Islamic Azad University.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par79">Not applicable.</p></notes><notes id="FPar4" notes-type="COI-statement"><title><bold>Competing interests</bold></title><p id="Par80">The authors declare no conflict of interest, financial or otherwise.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Acter</surname><given-names>T</given-names></name><name><surname>Uddin</surname><given-names>N</given-names></name><name><surname>Das</surname><given-names>J</given-names></name><name><surname>Akhter</surname><given-names>A</given-names></name><name><surname>Choudhury</surname><given-names>TR</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name></person-group><article-title>Evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as coronavirus disease 2019 (COVID-19) pandemic: a global health emergency</article-title><source>Sci Total Environ</source><year>2020</year><volume>730</volume><fpage>138996</fpage><?supplied-pmid 32371230?><pub-id pub-id-type="pmid">32371230</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Acter T, Uddin N, Das J, Akhter A, Choudhury TR, Kim S. Evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as coronavirus disease 2019 (COVID-19) pandemic: a global health emergency. Sci Total Environ. 2020;730: 138996.<pub-id pub-id-type="pmid">32371230</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Pal</surname><given-names>M</given-names></name><name><surname>Berhanu</surname><given-names>G</given-names></name><name><surname>Desalegn</surname><given-names>C</given-names></name><name><surname>Kandi</surname><given-names>V</given-names></name></person-group><article-title>Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): an update</article-title><source>Cureus</source><year>2020</year><?supplied-pmid 33354484?><pub-id pub-id-type="pmid">33354484</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Pal M, Berhanu G, Desalegn C, Kandi V. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): an update. Cureus. 2020. 10.7759/cureus.7423.<pub-id pub-id-type="pmid">33354484</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Raesi</surname><given-names>R</given-names></name><name><surname>Abbasi</surname><given-names>Z</given-names></name><name><surname>Raei</surname><given-names>M</given-names></name><name><surname>Hushmandi</surname><given-names>K</given-names></name></person-group><article-title>The relationship between the incidence of COVID-19 with the underlying diseases in hospitalized patients</article-title><source>EBNESINA</source><year>2022</year><volume>24</volume><issue>3</issue><fpage>75</fpage><lpage>80</lpage></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Raesi R, Abbasi Z, Raei M, Hushmandi K. The relationship between the incidence of COVID-19 with the underlying diseases in hospitalized patients. EBNESINA. 2022;24(3):75&#x02013;80.</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Renu</surname><given-names>K</given-names></name><name><surname>Prasanna</surname><given-names>PL</given-names></name><name><surname>Gopalakrishnan</surname><given-names>AV</given-names></name></person-group><article-title>Coronaviruses pathogenesis, comorbidities and multi-organ damage&#x02013;a review</article-title><source>Life Sci</source><year>2020</year><volume>255</volume><fpage>117839</fpage><?supplied-pmid 32450165?><pub-id pub-id-type="pmid">32450165</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Renu K, Prasanna PL, Gopalakrishnan AV. Coronaviruses pathogenesis, comorbidities and multi-organ damage&#x02013;a review. Life Sci. 2020;255: 117839.<pub-id pub-id-type="pmid">32450165</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Lund</surname><given-names>LC</given-names></name><name><surname>Hallas</surname><given-names>J</given-names></name><name><surname>Nielsen</surname><given-names>H</given-names></name><name><surname>Koch</surname><given-names>A</given-names></name><name><surname>Mogensen</surname><given-names>SH</given-names></name><name><surname>Brun</surname><given-names>NC</given-names></name><name><surname>Christiansen</surname><given-names>CF</given-names></name><name><surname>Thomsen</surname><given-names>RW</given-names></name><name><surname>Potteg&#x000e5;rd</surname><given-names>A</given-names></name></person-group><article-title>Post-acute effects of SARS-CoV-2 infection in individuals not requiring hospital admission: a Danish population-based cohort study</article-title><source>Lancet Infect Dis</source><year>2021</year><volume>21</volume><issue>10</issue><fpage>1373</fpage><lpage>82</lpage><?supplied-pmid 33984263?><pub-id pub-id-type="pmid">33984263</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Lund LC, Hallas J, Nielsen H, Koch A, Mogensen SH, Brun NC, Christiansen CF, Thomsen RW, Potteg&#x000e5;rd A. Post-acute effects of SARS-CoV-2 infection in individuals not requiring hospital admission: a Danish population-based cohort study. Lancet Infect Dis. 2021;21(10):1373&#x02013;82.<pub-id pub-id-type="pmid">33984263</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Aly</surname><given-names>Z</given-names></name><name><surname>Bowe</surname><given-names>B</given-names></name><name><surname>Xie</surname><given-names>Y</given-names></name></person-group><article-title>Long COVID after breakthrough SARS-CoV-2 infection</article-title><source>Nat Med</source><year>2022</year><volume>28</volume><issue>7</issue><fpage>1461</fpage><lpage>7</lpage><?supplied-pmid 35614233?><pub-id pub-id-type="pmid">35614233</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat Med. 2022;28(7):1461&#x02013;7.<pub-id pub-id-type="pmid">35614233</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Aiyegbusi</surname><given-names>OL</given-names></name><name><surname>Hughes</surname><given-names>SE</given-names></name><name><surname>Turner</surname><given-names>G</given-names></name><name><surname>Rivera</surname><given-names>SC</given-names></name><name><surname>McMullan</surname><given-names>C</given-names></name><name><surname>Chandan</surname><given-names>JS</given-names></name><name><surname>Haroon</surname><given-names>S</given-names></name><name><surname>Price</surname><given-names>G</given-names></name><name><surname>Davies</surname><given-names>EH</given-names></name><name><surname>Nirantharakumar</surname><given-names>K</given-names></name></person-group><article-title>Symptoms, complications and management of long COVID: a review</article-title><source>J R Soc Med</source><year>2021</year><volume>114</volume><issue>9</issue><fpage>428</fpage><lpage>42</lpage><?supplied-pmid 34265229?><pub-id pub-id-type="pmid">34265229</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Aiyegbusi OL, Hughes SE, Turner G, Rivera SC, McMullan C, Chandan JS, Haroon S, Price G, Davies EH, Nirantharakumar K. Symptoms, complications and management of long COVID: a review. J R Soc Med. 2021;114(9):428&#x02013;42.<pub-id pub-id-type="pmid">34265229</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Fern&#x000e1;ndez-de-Las-Pe&#x000f1;as</surname><given-names>C</given-names></name><name><surname>Palacios-Ce&#x000f1;a</surname><given-names>D</given-names></name><name><surname>G&#x000f3;mez-Mayordomo</surname><given-names>V</given-names></name><name><surname>Cuadrado</surname><given-names>ML</given-names></name><name><surname>Florencio</surname><given-names>LL</given-names></name></person-group><article-title>Defining post-COVID symptoms (post-acute COVID, long COVID, persistent post-COVID): an integrative classification</article-title><source>Int J Environ Res Public Health</source><year>2021</year><volume>18</volume><issue>5</issue><fpage>2621</fpage><?supplied-pmid 33807869?><pub-id pub-id-type="pmid">33807869</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Fern&#x000e1;ndez-de-Las-Pe&#x000f1;as C, Palacios-Ce&#x000f1;a D, G&#x000f3;mez-Mayordomo V, Cuadrado ML, Florencio LL. Defining post-COVID symptoms (post-acute COVID, long COVID, persistent post-COVID): an integrative classification. Int J Environ Res Public Health. 2021;18(5): 2621.<pub-id pub-id-type="pmid">33807869</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Abbasi</surname><given-names>Z</given-names></name><name><surname>Moghadaci</surname><given-names>A</given-names></name><name><surname>Mohammadnahal</surname><given-names>L</given-names></name><name><surname>Sangrizeh</surname><given-names>FH</given-names></name><name><surname>Gholami</surname><given-names>MH</given-names></name><name><surname>Baeelashaki</surname><given-names>R</given-names></name><name><surname>Hushmandi</surname><given-names>K</given-names></name><name><surname>Raesi</surname><given-names>R</given-names></name><name><surname>Khalilipour</surname><given-names>A</given-names></name><name><surname>Dashti</surname><given-names>S</given-names></name></person-group><article-title>Investigating how interleukin 6 serum level, blood group type, and underlying diseases are associated in patients admitted to the COVID-19 intensive care unit: a retrospective study</article-title><source>Open Public Health J</source><year>2023</year></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Abbasi Z, Moghadaci A, Mohammadnahal L, Sangrizeh FH, Gholami MH, Baeelashaki R, Hushmandi K, Raesi R, Khalilipour A, Dashti S. Investigating how interleukin 6 serum level, blood group type, and underlying diseases are associated in patients admitted to the COVID-19 intensive care unit: a retrospective study. Open Public Health J. 2023. 10.2174/0118749445258188230922115257.</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Pierce</surname><given-names>JD</given-names></name><name><surname>Shen</surname><given-names>Q</given-names></name><name><surname>Cintron</surname><given-names>SA</given-names></name><name><surname>Hiebert</surname><given-names>JB</given-names></name></person-group><article-title>Post-COVID-19 syndrome</article-title><source>Nurs Res</source><year>2022</year><volume>71</volume><issue>2</issue><fpage>164</fpage><lpage>74</lpage><?supplied-pmid 34653099?><pub-id pub-id-type="pmid">34653099</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Pierce JD, Shen Q, Cintron SA, Hiebert JB. Post-COVID-19 syndrome. Nurs Res. 2022;71(2):164&#x02013;74.<pub-id pub-id-type="pmid">34653099</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Oronsky</surname><given-names>B</given-names></name><name><surname>Larson</surname><given-names>C</given-names></name><name><surname>Hammond</surname><given-names>TC</given-names></name><name><surname>Oronsky</surname><given-names>A</given-names></name><name><surname>Kesari</surname><given-names>S</given-names></name><name><surname>Lybeck</surname><given-names>M</given-names></name><name><surname>Reid</surname><given-names>TR</given-names></name></person-group><article-title>A review of persistent post-COVID syndrome (PPCS)</article-title><source>Clin Rev Allergy Immunol</source><year>2023</year><volume>64</volume><issue>1</issue><fpage>66</fpage><lpage>74</lpage><?supplied-pmid 33609255?><pub-id pub-id-type="pmid">33609255</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Oronsky B, Larson C, Hammond TC, Oronsky A, Kesari S, Lybeck M, Reid TR. A review of persistent post-COVID syndrome (PPCS). Clin Rev Allergy Immunol. 2023;64(1):66&#x02013;74.<pub-id pub-id-type="pmid">33609255</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Yong</surname><given-names>SJ</given-names></name></person-group><article-title>Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments</article-title><source>Infect Dis</source><year>2021</year><volume>53</volume><issue>10</issue><fpage>737</fpage><lpage>54</lpage></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Yong SJ. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infect Dis. 2021;53(10):737&#x02013;54.</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Lechner-Scott</surname><given-names>J</given-names></name><name><surname>Levy</surname><given-names>M</given-names></name><name><surname>Hawkes</surname><given-names>C</given-names></name><name><surname>Yeh</surname><given-names>A</given-names></name><name><surname>Giovannoni</surname><given-names>G</given-names></name></person-group><article-title>Long COVID or post COVID-19 syndrome</article-title><source>Mult Scler Relat Disord</source><year>2021</year><?supplied-pmid 35216788?><pub-id pub-id-type="pmid">35216788</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Lechner-Scott J, Levy M, Hawkes C, Yeh A, Giovannoni G. Long COVID or post COVID-19 syndrome. Mult Scler Relat Disord. 2021. 10.1016/j.msard.2021.103268.<pub-id pub-id-type="pmid">35216788</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Scordo</surname><given-names>KA</given-names></name><name><surname>Richmond</surname><given-names>MM</given-names></name><name><surname>Munro</surname><given-names>N</given-names></name></person-group><article-title>Post&#x02013;COVID-19 syndrome: theoretical basis, identification, and management</article-title><source>AACN Adv Crit Care</source><year>2021</year><volume>32</volume><issue>2</issue><fpage>188</fpage><lpage>94</lpage><?supplied-pmid 33942071?><pub-id pub-id-type="pmid">33942071</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Scordo KA, Richmond MM, Munro N. Post&#x02013;COVID-19 syndrome: theoretical basis, identification, and management. AACN Adv Crit Care. 2021;32(2):188&#x02013;94.<pub-id pub-id-type="pmid">33942071</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Carod-Artal</surname><given-names>FJ</given-names></name></person-group><article-title>Post-COVID-19 syndrome: epidemiology, diagnostic criteria and pathogenic mechanisms involved</article-title><source>Rev Neurol</source><year>2021</year><volume>72</volume><issue>11</issue><fpage>384</fpage><lpage>96</lpage><?supplied-pmid 34042167?><pub-id pub-id-type="pmid">34042167</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Carod-Artal FJ. Post-COVID-19 syndrome: epidemiology, diagnostic criteria and pathogenic mechanisms involved. Rev Neurol. 2021;72(11):384&#x02013;96.<pub-id pub-id-type="pmid">34042167</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Maltezou</surname><given-names>HC</given-names></name><name><surname>Pavli</surname><given-names>A</given-names></name><name><surname>Tsakris</surname><given-names>A</given-names></name></person-group><article-title>Post-COVID syndrome: an insight on its pathogenesis</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><issue>5</issue><fpage>497</fpage><?supplied-pmid 34066007?><pub-id pub-id-type="pmid">34066007</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Maltezou HC, Pavli A, Tsakris A. Post-COVID syndrome: an insight on its pathogenesis. Vaccines. 2021;9(5):497.<pub-id pub-id-type="pmid">34066007</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Raveendran</surname><given-names>A</given-names></name><name><surname>Misra</surname><given-names>A</given-names></name></person-group><article-title>Post COVID-19 syndrome (long COVID) and diabetes: challenges in diagnosis and management</article-title><source>Diabetes &#x00026; Metabolic Syndrome: Clinical Research &#x00026; Reviews</source><year>2021</year><volume>15</volume><issue>5</issue><fpage>102235</fpage></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Raveendran A, Misra A. Post COVID-19 syndrome (long COVID) and diabetes: challenges in diagnosis and management. Diabetes &#x00026; Metabolic Syndrome: Clinical Research &#x00026; Reviews. 2021;15(5): 102235.</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Nalbandian</surname><given-names>A</given-names></name><name><surname>Sehgal</surname><given-names>K</given-names></name><name><surname>Gupta</surname><given-names>A</given-names></name><name><surname>Madhavan</surname><given-names>MV</given-names></name><name><surname>McGroder</surname><given-names>C</given-names></name><name><surname>Stevens</surname><given-names>JS</given-names></name><name><surname>Cook</surname><given-names>JR</given-names></name><name><surname>Nordvig</surname><given-names>AS</given-names></name><name><surname>Shalev</surname><given-names>D</given-names></name><name><surname>Sehrawat</surname><given-names>TS</given-names></name></person-group><article-title>Post-acute COVID-19 syndrome</article-title><source>Nat Med</source><year>2021</year><volume>27</volume><issue>4</issue><fpage>601</fpage><lpage>15</lpage><?supplied-pmid 33753937?><pub-id pub-id-type="pmid">33753937</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, Cook JR, Nordvig AS, Shalev D, Sehrawat TS. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601&#x02013;15.<pub-id pub-id-type="pmid">33753937</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuishi</surname><given-names>Y</given-names></name><name><surname>Mathis</surname><given-names>BJ</given-names></name><name><surname>Shimojo</surname><given-names>N</given-names></name><name><surname>Subrina</surname><given-names>J</given-names></name><name><surname>Okubo</surname><given-names>N</given-names></name><name><surname>Inoue</surname><given-names>Y</given-names></name></person-group><article-title>Severe COVID-19 infection associated with endothelial dysfunction induces multiple organ dysfunction: a review of therapeutic interventions</article-title><source>Biomedicines</source><year>2021</year><volume>9</volume><issue>3</issue><fpage>279</fpage><?supplied-pmid 33801921?><pub-id pub-id-type="pmid">33801921</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Matsuishi Y, Mathis BJ, Shimojo N, Subrina J, Okubo N, Inoue Y. Severe COVID-19 infection associated with endothelial dysfunction induces multiple organ dysfunction: a review of therapeutic interventions. Biomedicines. 2021;9(3):279.<pub-id pub-id-type="pmid">33801921</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>See&#x000df;le</surname><given-names>J</given-names></name><name><surname>Waterboer</surname><given-names>T</given-names></name><name><surname>Hippchen</surname><given-names>T</given-names></name><name><surname>Simon</surname><given-names>J</given-names></name><name><surname>Kirchner</surname><given-names>M</given-names></name><name><surname>Lim</surname><given-names>A</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>B</given-names></name><name><surname>Merle</surname><given-names>U</given-names></name></person-group><article-title>Persistent symptoms in adult patients 1 year after coronavirus disease 2019 (COVID-19): a prospective cohort study</article-title><source>Clin Infect Dis</source><year>2022</year><volume>74</volume><issue>7</issue><fpage>1191</fpage><lpage>8</lpage><?supplied-pmid 34223884?><pub-id pub-id-type="pmid">34223884</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">See&#x000df;le J, Waterboer T, Hippchen T, Simon J, Kirchner M, Lim A, M&#x000fc;ller B, Merle U. Persistent symptoms in adult patients 1 year after coronavirus disease 2019 (COVID-19): a prospective cohort study. Clin Infect Dis. 2022;74(7):1191&#x02013;8.<pub-id pub-id-type="pmid">34223884</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Whitaker</surname><given-names>M</given-names></name><name><surname>Elliott</surname><given-names>J</given-names></name><name><surname>Chadeau-Hyam</surname><given-names>M</given-names></name><name><surname>Riley</surname><given-names>S</given-names></name><name><surname>Darzi</surname><given-names>A</given-names></name><name><surname>Cooke</surname><given-names>G</given-names></name><name><surname>Ward</surname><given-names>H</given-names></name><name><surname>Elliott</surname><given-names>P</given-names></name></person-group><article-title>Persistent COVID-19 symptoms in a community study of 606,434 people in England</article-title><source>Nat Commun</source><year>2022</year><volume>13</volume><issue>1</issue><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">34983933</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Whitaker M, Elliott J, Chadeau-Hyam M, Riley S, Darzi A, Cooke G, Ward H, Elliott P. Persistent COVID-19 symptoms in a community study of 606,434 people in England. Nat Commun. 2022;13(1):1&#x02013;10.<pub-id pub-id-type="pmid">34983933</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Uzunova</surname><given-names>G</given-names></name><name><surname>Pallanti</surname><given-names>S</given-names></name><name><surname>Hollander</surname><given-names>E</given-names></name></person-group><article-title>Presentation and management of anxiety in individuals with acute symptomatic or asymptomatic COVID-19 infection, and in the post-COVID-19 recovery phase</article-title><source>Int J Psychiatry Clin Pract</source><year>2021</year><volume>25</volume><issue>2</issue><fpage>115</fpage><lpage>31</lpage><?supplied-pmid 33635172?><pub-id pub-id-type="pmid">33635172</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Uzunova G, Pallanti S, Hollander E. Presentation and management of anxiety in individuals with acute symptomatic or asymptomatic COVID-19 infection, and in the post-COVID-19 recovery phase. Int J Psychiatry Clin Pract. 2021;25(2):115&#x02013;31.<pub-id pub-id-type="pmid">33635172</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Hao</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Prevalence and risk factors of mental health problems among healthcare workers during the COVID-19 pandemic: a systematic review and meta-analysis</article-title><source>Front Psychiatry</source><year>2021</year><volume>12</volume><fpage>567381</fpage><?supplied-pmid 34211406?><pub-id pub-id-type="pmid">34211406</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Hao Q, et al. Prevalence and risk factors of mental health problems among healthcare workers during the COVID-19 pandemic: a systematic review and meta-analysis. Front Psychiatry. 2021;12:567381.<pub-id pub-id-type="pmid">34211406</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="book"><person-group person-group-type="author"><name><surname>Lans</surname><given-names>TJ</given-names></name></person-group><source>Long COVID patients: a phenomenology study exploring mental health and psychosocial adaptation to disability</source><year>2024</year><publisher-loc>Michigan</publisher-loc><publisher-name>Western Michigan University</publisher-name></element-citation><mixed-citation id="mc-CR24" publication-type="book">Lans TJ. Long COVID patients: a phenomenology study exploring mental health and psychosocial adaptation to disability. Michigan: Western Michigan University; 2024.</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Abdul-Mumin</surname><given-names>KH</given-names></name><name><surname>Maideen</surname><given-names>AA</given-names></name><name><surname>Lupat</surname><given-names>A</given-names></name><name><surname>Mohd-Alipah</surname><given-names>SN-D</given-names></name><name><surname>Mohammad-Alli</surname><given-names>RH</given-names></name><name><surname>Abd-Manaf</surname><given-names>H-NH</given-names></name><name><surname>Osman</surname><given-names>A-R</given-names></name><name><surname>Abd. Fata</surname><given-names>HMR</given-names></name><name><surname>Busrah</surname><given-names>N</given-names></name><name><surname>Darling-Fisher</surname><given-names>C</given-names></name></person-group><article-title>Embracing the inner strength and staying strong: exploring Self-Care preparedness among nurses for enhancing their psychological Well-Being against the Long-Term effect of COVID-19 pandemic in Brunei Darussalam</article-title><source>Int J Environ Res Public Health</source><year>2023</year><volume>20</volume><issue>17</issue><fpage>6629</fpage><?supplied-pmid 37681769?><pub-id pub-id-type="pmid">37681769</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Abdul-Mumin KH, Maideen AA, Lupat A, Mohd-Alipah SN-D, Mohammad-Alli RH, Abd-Manaf H-NH, Osman A-R, Abd. Fata HMR, Busrah N, Darling-Fisher C. Embracing the inner strength and staying strong: exploring Self-Care preparedness among nurses for enhancing their psychological Well-Being against the Long-Term effect of COVID-19 pandemic in Brunei Darussalam. Int J Environ Res Public Health. 2023;20(17):6629.<pub-id pub-id-type="pmid">37681769</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Ivancsits</surname><given-names>S</given-names></name><name><surname>Diem</surname><given-names>E</given-names></name><name><surname>Pilger</surname><given-names>A</given-names></name><name><surname>R&#x000fc;diger</surname><given-names>HW</given-names></name><name><surname>Jahn</surname><given-names>O</given-names></name></person-group><article-title>Induction of DNA strand breaks by intermittent exposure to extremely-low-frequency electromagnetic fields in human diploid fibroblasts</article-title><source>Mutat Res-Genet Toxicol Environ Mutagen</source><year>2002</year><volume>519</volume><issue>1&#x02013;2</issue><fpage>1</fpage><lpage>13</lpage></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Ivancsits S, Diem E, Pilger A, R&#x000fc;diger HW, Jahn O. Induction of DNA strand breaks by intermittent exposure to extremely-low-frequency electromagnetic fields in human diploid fibroblasts. Mutat Res-Genet Toxicol Environ Mutagen. 2002;519(1&#x02013;2):1&#x02013;13.</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>N</given-names></name><name><surname>Parrish</surname><given-names>M</given-names></name><name><surname>Chan</surname><given-names>TK</given-names></name><name><surname>Yin</surname><given-names>L</given-names></name><name><surname>Rai</surname><given-names>P</given-names></name><name><surname>Yoshiyuki</surname><given-names>Y</given-names></name><name><surname>Abolhassani</surname><given-names>N</given-names></name><name><surname>Tan</surname><given-names>KB</given-names></name><name><surname>Kiraly</surname><given-names>O</given-names></name><name><surname>Chow</surname><given-names>VT</given-names></name></person-group><article-title>Influenza infection induces host DNA damage and dynamic DNA damage responses during tissue regeneration</article-title><source>Cell Mol Life Sci</source><year>2015</year><volume>72</volume><fpage>2973</fpage><lpage>88</lpage><?supplied-pmid 25809161?><pub-id pub-id-type="pmid">25809161</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Li N, Parrish M, Chan TK, Yin L, Rai P, Yoshiyuki Y, Abolhassani N, Tan KB, Kiraly O, Chow VT. Influenza infection induces host DNA damage and dynamic DNA damage responses during tissue regeneration. Cell Mol Life Sci. 2015;72:2973&#x02013;88.<pub-id pub-id-type="pmid">25809161</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Foppa</surname><given-names>L</given-names></name><name><surname>Mota ALRd</surname><given-names>M</given-names></name></person-group><article-title>Quality of life and eating habits of patients with obesity during the COVID-19 pandemic</article-title><source>Rev Latinoam Enferm</source><year>2021</year><volume>29</volume><fpage>e3502</fpage></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Foppa L, Mota ALRd M. Quality of life and eating habits of patients with obesity during the COVID-19 pandemic. Rev Latinoam Enferm. 2021;29:e3502.</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>J</given-names></name><name><surname>Oh</surname><given-names>E</given-names></name><name><surname>Kim</surname><given-names>Y</given-names></name><name><surname>Jung</surname><given-names>W</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Sul</surname><given-names>D</given-names></name></person-group><article-title>Enhanced oxidative damage to DNA, lipids, and proteins and levels of some antioxidant enzymes, cytokines, and heat shock proteins in patients infected with influenza H1N1 virus</article-title><source>Acta Virol</source><year>2014</year><volume>58</volume><issue>3</issue><fpage>253</fpage><lpage>60</lpage><?supplied-pmid 25283860?><pub-id pub-id-type="pmid">25283860</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Lim J, Oh E, Kim Y, Jung W, Kim H, Lee J, Sul D. Enhanced oxidative damage to DNA, lipids, and proteins and levels of some antioxidant enzymes, cytokines, and heat shock proteins in patients infected with influenza H1N1 virus. Acta Virol. 2014;58(3):253&#x02013;60.<pub-id pub-id-type="pmid">25283860</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><mixed-citation publication-type="other">Ng MP, Lee JC, Loke WM, Yeo LL, Quek AM, Lim EC, Halliwell B, Seet RC-S: does influenza A infection increase oxidative damage? In: Mary Ann Liebert, Inc. 140 Huguenot Street, 3rd Floor New Rochelle, NY 10801 USA; 2014.</mixed-citation></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Cares-Marambio</surname><given-names>K</given-names></name><name><surname>Montenegro-Jim&#x000e9;nez</surname><given-names>Y</given-names></name><name><surname>Torres-Castro</surname><given-names>R</given-names></name><name><surname>Vera-Uribe</surname><given-names>R</given-names></name><name><surname>Torralba</surname><given-names>Y</given-names></name><name><surname>Alsina-Restoy</surname><given-names>X</given-names></name><name><surname>Vasconcello-Castillo</surname><given-names>L</given-names></name><name><surname>Vilar&#x000f3;</surname><given-names>J</given-names></name></person-group><article-title>Prevalence of potential respiratory symptoms in survivors of hospital admission after coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis</article-title><source>Chron Respir Dis</source><year>2021</year><volume>18</volume><fpage>14799731211002240</fpage><?supplied-pmid 33729021?><pub-id pub-id-type="pmid">33729021</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Cares-Marambio K, Montenegro-Jim&#x000e9;nez Y, Torres-Castro R, Vera-Uribe R, Torralba Y, Alsina-Restoy X, Vasconcello-Castillo L, Vilar&#x000f3; J. Prevalence of potential respiratory symptoms in survivors of hospital admission after coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. Chron Respir Dis. 2021;18: 14799731211002240.<pub-id pub-id-type="pmid">33729021</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Fern&#x000e1;ndez-de-Las-Pe&#x000f1;as</surname><given-names>C&#x000e9;sar</given-names></name><etal/></person-group><article-title>Defining post-COVID symptoms (post-acute COVID, long COVID, persistent post-COVID): an integrative classification</article-title><source>Int J Environ Res Public Health</source><year>2021</year><volume>18</volume><issue>5</issue><fpage>2621</fpage><?supplied-pmid 33807869?><pub-id pub-id-type="pmid">33807869</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Fern&#x000e1;ndez-de-Las-Pe&#x000f1;as C&#x000e9;sar, et al. Defining post-COVID symptoms (post-acute COVID, long COVID, persistent post-COVID): an integrative classification. Int J Environ Res Public Health. 2021;18(5): 2621.<pub-id pub-id-type="pmid">33807869</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Moody</surname><given-names>WE</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Mahmoud-Elsayed</surname><given-names>HM</given-names></name><name><surname>Senior</surname><given-names>J</given-names></name><name><surname>Lalla</surname><given-names>SS</given-names></name><name><surname>Khan-Kheil</surname><given-names>AM</given-names></name><name><surname>Brown</surname><given-names>S</given-names></name><name><surname>Saif</surname><given-names>A</given-names></name><name><surname>Moss</surname><given-names>A</given-names></name><name><surname>Bradlow</surname><given-names>WM</given-names></name></person-group><article-title>Persisting adverse ventricular remodeling in COVID-19 survivors: a longitudinal echocardiographic study</article-title><source>J Am Soc Echocardiogr</source><year>2021</year><volume>34</volume><issue>5</issue><fpage>562</fpage><?supplied-pmid 33539950?><pub-id pub-id-type="pmid">33539950</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Moody WE, Liu B, Mahmoud-Elsayed HM, Senior J, Lalla SS, Khan-Kheil AM, Brown S, Saif A, Moss A, Bradlow WM. Persisting adverse ventricular remodeling in COVID-19 survivors: a longitudinal echocardiographic study. J Am Soc Echocardiogr. 2021;34(5):562.<pub-id pub-id-type="pmid">33539950</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Miwa</surname><given-names>M</given-names></name><name><surname>Nakajima</surname><given-names>M</given-names></name><name><surname>Kaszynski</surname><given-names>RH</given-names></name><name><surname>Hamada</surname><given-names>S</given-names></name><name><surname>Ando</surname><given-names>H</given-names></name><name><surname>Nakano</surname><given-names>T</given-names></name><name><surname>Shirokawa</surname><given-names>M</given-names></name><name><surname>Goto</surname><given-names>H</given-names></name></person-group><article-title>Abnormal pulmonary function and imaging studies in critical COVID-19 survivors at 100 days after the onset of symptoms</article-title><source>Respir Investig</source><year>2021</year><volume>59</volume><issue>5</issue><fpage>614</fpage><lpage>21</lpage><?supplied-pmid 34148855?><pub-id pub-id-type="pmid">34148855</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Miwa M, Nakajima M, Kaszynski RH, Hamada S, Ando H, Nakano T, Shirokawa M, Goto H. Abnormal pulmonary function and imaging studies in critical COVID-19 survivors at 100 days after the onset of symptoms. Respir Investig. 2021;59(5):614&#x02013;21.<pub-id pub-id-type="pmid">34148855</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Chopra</surname><given-names>V</given-names></name><name><surname>Flanders</surname><given-names>SA</given-names></name><name><surname>O&#x02019;Malley</surname><given-names>M</given-names></name><name><surname>Malani</surname><given-names>AN</given-names></name><name><surname>Prescott</surname><given-names>HC</given-names></name></person-group><article-title>Sixty-day outcomes among patients hospitalized with COVID-19</article-title><source>Ann Intern Med</source><year>2021</year><volume>174</volume><issue>4</issue><fpage>576</fpage><lpage>8</lpage><?supplied-pmid 33175566?><pub-id pub-id-type="pmid">33175566</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Chopra V, Flanders SA, O&#x02019;Malley M, Malani AN, Prescott HC. Sixty-day outcomes among patients hospitalized with COVID-19. Ann Intern Med. 2021;174(4):576&#x02013;8.<pub-id pub-id-type="pmid">33175566</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Shelley</surname><given-names>J</given-names></name><name><surname>Hudson</surname><given-names>J</given-names></name><name><surname>Mackintosh</surname><given-names>KA</given-names></name><name><surname>Saynor</surname><given-names>ZL</given-names></name><name><surname>Duckers</surname><given-names>J</given-names></name><name><surname>Lewis</surname><given-names>KE</given-names></name><name><surname>Davies</surname><given-names>GA</given-names></name><name><surname>Berg</surname><given-names>RM</given-names></name><name><surname>McNarry</surname><given-names>MA</given-names></name></person-group><article-title>I live a kind of shadow life&#x02019;: individual experiences of COVID-19 recovery and the impact on physical activity levels</article-title><source>Int J Environ Res Public Health</source><year>2021</year><volume>18</volume><issue>21</issue><fpage>11417</fpage><?supplied-pmid 34769934?><pub-id pub-id-type="pmid">34769934</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Shelley J, Hudson J, Mackintosh KA, Saynor ZL, Duckers J, Lewis KE, Davies GA, Berg RM, McNarry MA. I live a kind of shadow life&#x02019;: individual experiences of COVID-19 recovery and the impact on physical activity levels. Int J Environ Res Public Health. 2021;18(21): 11417.<pub-id pub-id-type="pmid">34769934</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Pavli</surname><given-names>A</given-names></name><name><surname>Theodoridou</surname><given-names>M</given-names></name><name><surname>Maltezou</surname><given-names>HC</given-names></name></person-group><article-title>Post-COVID syndrome: incidence, clinical spectrum, and challenges for primary healthcare professionals</article-title><source>Arch Med Res</source><year>2021</year><volume>52</volume><issue>6</issue><fpage>575</fpage><lpage>81</lpage><?supplied-pmid 33962805?><pub-id pub-id-type="pmid">33962805</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Pavli A, Theodoridou M, Maltezou HC. Post-COVID syndrome: incidence, clinical spectrum, and challenges for primary healthcare professionals. Arch Med Res. 2021;52(6):575&#x02013;81.<pub-id pub-id-type="pmid">33962805</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Patterson</surname><given-names>BK</given-names></name><name><surname>Guevara-Coto</surname><given-names>J</given-names></name><name><surname>Yogendra</surname><given-names>R</given-names></name><name><surname>Francisco</surname><given-names>EB</given-names></name><name><surname>Long</surname><given-names>E</given-names></name><name><surname>Pise</surname><given-names>A</given-names></name><name><surname>Rodrigues</surname><given-names>H</given-names></name><name><surname>Parikh</surname><given-names>P</given-names></name><name><surname>Mora</surname><given-names>J</given-names></name><name><surname>Mora-Rodr&#x000ed;guez</surname><given-names>RA</given-names></name></person-group><article-title>Immune-based prediction of COVID-19 severity and chronicity decoded using machine learning</article-title><source>Front Immunol</source><year>2021</year><volume>12</volume><fpage>700782</fpage><?supplied-pmid 34262570?><pub-id pub-id-type="pmid">34262570</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">Patterson BK, Guevara-Coto J, Yogendra R, Francisco EB, Long E, Pise A, Rodrigues H, Parikh P, Mora J, Mora-Rodr&#x000ed;guez RA. Immune-based prediction of COVID-19 severity and chronicity decoded using machine learning. Front Immunol. 2021;12:700782.<pub-id pub-id-type="pmid">34262570</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Ramakrishnan</surname><given-names>RK</given-names></name><name><surname>Kashour</surname><given-names>T</given-names></name><name><surname>Hamid</surname><given-names>Q</given-names></name><name><surname>Halwani</surname><given-names>R</given-names></name><name><surname>Tleyjeh</surname><given-names>IM</given-names></name></person-group><article-title>Unraveling the mystery surrounding post-acute sequelae of COVID-19</article-title><source>Front Immunol</source><year>2021</year><volume>12</volume><fpage>686029</fpage><?supplied-pmid 34276671?><pub-id pub-id-type="pmid">34276671</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Ramakrishnan RK, Kashour T, Hamid Q, Halwani R, Tleyjeh IM. Unraveling the mystery surrounding post-acute sequelae of COVID-19. Front Immunol. 2021;12:686029.<pub-id pub-id-type="pmid">34276671</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Bezerra</surname><given-names>FS</given-names></name><name><surname>Lanzetti</surname><given-names>M</given-names></name><name><surname>Nesi</surname><given-names>RT</given-names></name><name><surname>Nagato</surname><given-names>AC</given-names></name><name><surname>Silva CPe, Kennedy-Feitosa</surname><given-names>E</given-names></name><name><surname>Melo</surname><given-names>AC</given-names></name><name><surname>Cattani-Cavalieri</surname><given-names>I</given-names></name><name><surname>Porto</surname><given-names>LC</given-names></name><name><surname>Valenca</surname><given-names>SS</given-names></name></person-group><article-title>Oxidative stress and inflammation in acute and chronic lung injuries</article-title><source>Antioxidants</source><year>2023</year><volume>12</volume><issue>3</issue><fpage>548</fpage><?supplied-pmid 36978796?><pub-id pub-id-type="pmid">36978796</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Bezerra FS, Lanzetti M, Nesi RT, Nagato AC, Silva CPe, Kennedy-Feitosa E, Melo AC, Cattani-Cavalieri I, Porto LC, Valenca SS. Oxidative stress and inflammation in acute and chronic lung injuries. Antioxidants. 2023;12(3):548.<pub-id pub-id-type="pmid">36978796</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>T-H</given-names></name><name><surname>Chang</surname><given-names>C-J</given-names></name><name><surname>Hung</surname><given-names>P-H</given-names></name></person-group><article-title>Possible pathogenesis and prevention of long COVID: SARS-CoV-2-induced mitochondrial disorder</article-title><source>Int J Mol Sci</source><year>2023</year><volume>24</volume><issue>9</issue><fpage>8034</fpage><?supplied-pmid 37175745?><pub-id pub-id-type="pmid">37175745</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Chen T-H, Chang C-J, Hung P-H. Possible pathogenesis and prevention of long COVID: SARS-CoV-2-induced mitochondrial disorder. Int J Mol Sci. 2023;24(9): 8034.<pub-id pub-id-type="pmid">37175745</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Rebholz</surname><given-names>H</given-names></name><name><surname>Braun</surname><given-names>RJ</given-names></name><name><surname>Ladage</surname><given-names>D</given-names></name><name><surname>Knoll</surname><given-names>W</given-names></name><name><surname>Kleber</surname><given-names>C</given-names></name><name><surname>Hassel</surname><given-names>AW</given-names></name></person-group><article-title>Loss of olfactory function&#x02014;early indicator for Covid-19, other viral infections and neurodegenerative disorders</article-title><source>Front Neurol</source><year>2020</year><volume>11</volume><fpage>569333</fpage><?supplied-pmid 33193009?><pub-id pub-id-type="pmid">33193009</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">Rebholz H, Braun RJ, Ladage D, Knoll W, Kleber C, Hassel AW. Loss of olfactory function&#x02014;early indicator for Covid-19, other viral infections and neurodegenerative disorders. Front Neurol. 2020;11:569333.<pub-id pub-id-type="pmid">33193009</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Kuwazoe</surname><given-names>H</given-names></name><name><surname>Sakatani</surname><given-names>H</given-names></name><name><surname>Kono</surname><given-names>M</given-names></name><name><surname>Saika</surname><given-names>S</given-names></name><name><surname>Inoue</surname><given-names>N</given-names></name><name><surname>Hotomi</surname><given-names>M</given-names></name></person-group><article-title>Complement component 3 promotes regeneration of olfactory receptor neurons</article-title><source>Lab Invest</source><year>2025</year><volume>105</volume><issue>2</issue><fpage>102200</fpage><?supplied-pmid 39581348?><pub-id pub-id-type="pmid">39581348</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Kuwazoe H, Sakatani H, Kono M, Saika S, Inoue N, Hotomi M. Complement component 3 promotes regeneration of olfactory receptor neurons. Lab Invest. 2025;105(2): 102200.<pub-id pub-id-type="pmid">39581348</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Queiroz</surname><given-names>MAF</given-names></name><name><surname>Brito</surname><given-names>WRS</given-names></name><name><surname>Pereira</surname><given-names>KAS</given-names></name><name><surname>Pereira</surname><given-names>LMS</given-names></name><name><surname>Amoras</surname><given-names>ESG</given-names></name><name><surname>Lima</surname><given-names>SS</given-names></name><name><surname>Santos</surname></name><name><surname>EFd</surname></name></person-group><article-title>Costa fpd, sarges kmld, Cantanhede MHD: severe COVID-19 and long COVID are associated with high expression of STING, cGAS and IFN-&#x003b1;</article-title><source>Sci Rep</source><year>2024</year><volume>14</volume><issue>1</issue><fpage>4974</fpage><?supplied-pmid 38424312?><pub-id pub-id-type="pmid">38424312</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Queiroz MAF, Brito WRS, Pereira KAS, Pereira LMS, Amoras ESG, Lima SS, Santos, EFd. Costa fpd, sarges kmld, Cantanhede MHD: severe COVID-19 and long COVID are associated with high expression of STING, cGAS and IFN-&#x003b1;. Sci Rep. 2024;14(1):4974.<pub-id pub-id-type="pmid">38424312</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Swaroop</surname><given-names>AK</given-names></name><name><surname>Negi</surname><given-names>P</given-names></name><name><surname>Kar</surname><given-names>A</given-names></name><name><surname>Mariappan</surname><given-names>E</given-names></name><name><surname>Natarajan</surname><given-names>J</given-names></name><name><surname>Krishnan Namboori</surname><given-names>PK</given-names></name><name><surname>Selvaraj</surname><given-names>J</given-names></name></person-group><article-title>Navigating IL-6: from molecular mechanisms to therapeutic breakthroughs</article-title><source>Cytokine Growth Factor Rev</source><year>2024</year><volume>76</volume><fpage>48</fpage><lpage>76</lpage><?supplied-pmid 38220583?><pub-id pub-id-type="pmid">38220583</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Swaroop AK, Negi P, Kar A, Mariappan E, Natarajan J, Krishnan Namboori PK, Selvaraj J. Navigating IL-6: from molecular mechanisms to therapeutic breakthroughs. Cytokine Growth Factor Rev. 2024;76:48&#x02013;76.<pub-id pub-id-type="pmid">38220583</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Sengupta</surname><given-names>P</given-names></name><name><surname>Dutta</surname><given-names>S</given-names></name></person-group><article-title>Does SARS-CoV-2 infection cause sperm DNA fragmentation? Possible link with oxidative stress</article-title><source>Eur J Contracept Reprod Health Care</source><year>2020</year><volume>25</volume><issue>5</issue><fpage>405</fpage><lpage>6</lpage><?supplied-pmid 32643968?><pub-id pub-id-type="pmid">32643968</pub-id>
</element-citation><mixed-citation id="mc-CR46" publication-type="journal">Sengupta P, Dutta S. Does SARS-CoV-2 infection cause sperm DNA fragmentation? Possible link with oxidative stress. Eur J Contracept Reprod Health Care. 2020;25(5):405&#x02013;6.<pub-id pub-id-type="pmid">32643968</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><mixed-citation publication-type="other">Koll L. The dual role of inflammation: acute versus chronic inflammation resulting from genomic instability in cancer. 2023.</mixed-citation></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Molnar</surname><given-names>T</given-names></name><name><surname>Lehoczki</surname><given-names>A</given-names></name><name><surname>Fekete</surname><given-names>M</given-names></name><name><surname>Varnai</surname><given-names>R</given-names></name><name><surname>Zavori</surname><given-names>L</given-names></name><name><surname>Erdo-Bonyar</surname><given-names>S</given-names></name><name><surname>Simon</surname><given-names>D</given-names></name><name><surname>Berki</surname><given-names>T</given-names></name><name><surname>Csecsei</surname><given-names>P</given-names></name><name><surname>Ezer</surname><given-names>E</given-names></name></person-group><article-title>Mitochondrial dysfunction in long COVID: mechanisms, consequences, and potential therapeutic approaches</article-title><source>Geroscience</source><year>2024</year><volume>46</volume><issue>5</issue><fpage>5267</fpage><lpage>86</lpage><?supplied-pmid 38668888?><pub-id pub-id-type="pmid">38668888</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">Molnar T, Lehoczki A, Fekete M, Varnai R, Zavori L, Erdo-Bonyar S, Simon D, Berki T, Csecsei P, Ezer E. Mitochondrial dysfunction in long COVID: mechanisms, consequences, and potential therapeutic approaches. Geroscience. 2024;46(5):5267&#x02013;86.<pub-id pub-id-type="pmid">38668888</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Qu</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>G-H</given-names></name></person-group><article-title>Roles of chromatin and genome instability in cellular senescence and their relevance to ageing and related diseases</article-title><source>Nat Rev Mol Cell Biol</source><year>2024</year><volume>25</volume><issue>12</issue><fpage>979</fpage><lpage>1000</lpage><?supplied-pmid 39363000?><pub-id pub-id-type="pmid">39363000</pub-id>
</element-citation><mixed-citation id="mc-CR49" publication-type="journal">Wu Z, Qu J, Liu G-H. Roles of chromatin and genome instability in cellular senescence and their relevance to ageing and related diseases. Nat Rev Mol Cell Biol. 2024;25(12):979&#x02013;1000.<pub-id pub-id-type="pmid">39363000</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>